Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

Risk Analysis

Volumn 24, Issue 6, 2004, Pages 1697-1717

  Clark, Leona H ^a   Setzer, R Woodrow ^a   Barton, Hugh A ^a,b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Model evaluation; PBPK models; Pharmacokinetics; Risk assessment

Indexed keywords

ACCIDENT PREVENTION; COMPUTATIONAL METHODS; DATA REDUCTION; MATHEMATICAL MODELS; PARAMETER ESTIMATION; PHARMACODYNAMICS; RISK ASSESSMENT; STATISTICAL METHODS;

BIOLOGICAL CHARACTERIZATION; PHARMACODYNAMIC EVENTS; POPULATION DISTRIBUTIONS; SIX-STEP PROCESSES;

PHARMACOKINETICS;

RISK ASSESSMENT;

BIOLOGICAL MODEL; CALIBRATION; COMPUTER PROGRAM; EXPERIMENTAL MODEL; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; POPULATION DISTRIBUTION; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL;

2-PROPANOL; ACETONE; ALGORITHMS; ANIMALS; CALIBRATION; COMPUTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; FEMALE; HUMANS; MATERNAL EXPOSURE; MODELS, THEORETICAL; PREGNANCY; RATS; RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SOFTWARE; SPECIES SPECIFICITY; STATISTICS; TISSUE DISTRIBUTION;

EID: 11344264355     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0272-4332.2004.00561.x     Document Type: Review

References (97)

1. Clewell III, H. J., Andersen, M. E., & Barton, H. A. (2002). A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environmental Health Perspectives, 110, 85-93.
2. Bois, F. Y., Woodruff, T. J., & Spear, R. C. (1991). Comparison of three physiologically based pharmacokinetic models of benzene disposition. Toxicology and Applied Pharmacology, 110, 79-88.
3. Woodruff, T. J., Bois, F. Y., Auslander, D., & Spear, R. C. (1992). Structure and parameterization of pharmacokinetic models: Their impact on model predictions. Risk Analysis, 12, 189-201.
4. Bois, F. Y. (1999). Analysis of PBPK models for risk characterization. Annals of New York Academy of Science, 895, 317-337.
5. Hattis, D., White, P., & Koch, P. (1993). Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. Risk Analysis, 13, 599-610.
6. Hattis, D., Banati, P., Goble, R., & Burmaster, D. E. (1999). Human interindividual variability in parameters related to health risks. Risk Analysis, 19, 711-726.
7. Kohn, M. C. (1995). Achieving credibility in risk assessment models. Toxicology Letters, 79, 107-114.
8. Portier, C. J., & Lyles, C. M. (1996). Practicing safe modeling: GLP for biologically based mechanistic models. Environmental Health Perspectives, 104, 806.
9. Andersen, M. E., Clewell III, H. J., & Frederick, C. B. (1995). Applying simulation modeling to problems in toxicology and risk assessment - A short perspective. Toxicology and Applied Pharmacology, 133, 181-187.
10. Gerlowski, L. E., & Jain, R. K. (1983). Physiologically based pharmacokinetic modeling: Principles and applications. Journal of Pharmaceutical Science, 72, 1103-1127.
11. Himmelstein, K. J., & Lutz, R. J. (1979). A review of the applications of physiologically based pharmacokinetic modeling. Journal of Pharmacokinetics and Biopharmaceutics, 7, 127-145.
12. Krishnan, K., & Andersen, M. E. (2001). Physiologically based pharmacokinetic modeling in toxicology. In A. Wallace Hayes (Ed.), Principles and Methods of Toxicology (pp. 193-241). Philadelphia: Taylor & Francis, Inc.
13. Medinsky, M. A., & Valentine, J. L. (2001). Toxicokinetics. In C. D. Klaassen (Ed.), Casarett and Doull's Toxicology: The Basic Science of Poisons (pp. 225-238). McGraw-Hill Professional.
14. Collins, A. S., Sumner, S. C., Borghoff, S. J., & Medinsky, M. A. (1999). A physiological model for tert-amyl methyl ether and tert-amyl alcohol: Hypothesis testing of model structures. Toxicological Science, 49, 15-28.
15. Bernillon, P., & Bois, F. Y. (2000). Statistical issues in toxicokinetic modeling: A Bayesian perspective. Environmental Health Perspectives, 108(Suppl. 5), 883-893.
16. Keys, D. A., Wallace, D. G., Kepler, T. B., & Conolly, R. B. (1999). Quantitative evaluation of alternative mechanisms of blood and testes disposition of di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate in rats. Toxicological Science, 49, 172-185.
17. Zartarian, V. G., Ozkaynak, H., Burke, J. M., Zufall, M. J., Rigas, M. L., & Furlaw Jr., E. J. (2000). A modeling framework for estimating children's residential exposure and dose to chlorpyrifos via dermal residue contact and nondietary ingeslion. Environmental Health Perspectives, 108, 505-514.
18. Price, P. S., Young, J. S., & Chaisson, C. F. (2001). Assessing aggregate and cumulative pesticide risks using a probabilistic model. Annals of Occuputational Hygine, 45(Suppl. 1), S131-S142.
19. Barton, H. A., & Andersen, M. E. (1998). Interaction of endocrine active compounds with the male central axis: A biologically based model for hormone regulation. In ILSI (Ed.), Human Diet and Endocrine Modulation: Estrogenic and Androgenic Effects (pp. 303-304). Washington, DC.
20. Conolly, R. B. (2002). The use of biologically based modeling in risk assessment. Toxicology, 181-182, 275-279.
21. Whitaker, S. Y., Tran, H. T., & Portier, C. J. (2003). Development of a biologically-based controlled growth and differentiation model for developmental toxicology. Journal of Mathematical Biology, 46, 1-16.
22. Barton, H. A., Andersen, M. E., & Clewell III, H. J. (1998). Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment. Human and Ecological Risk Assessment, 4, 75-115.
23. Bouchard, M., Brunet, R. C., Droz, P. O., & Carrier, G. (2001). A biologically based dynamic model for predicting the disposition of methanol and its metabolites in animals and humans. Toxicological Science, 64, 169-184.
24. Horton, V. L., Higuchi, M. A., & Rickert, D. E. (1992). Physiologically based pharmacokinetic model for methanol in rats, monkeys, and humans. Toxicology and Applied Pharmacology, 117, 26-36.
25. Rogers, J. M., Mole, M. L., Chernoff, N., Barbee, B. D., Turner, C. I., Logsdon, T. R., & Kavlock, R. J. (1993). The developmental toxicity of inhaled methanol in the CD-1 mouse, with quantitative dose-response modeling for estimation of benchmark doses. Teratology, 47, 175-188.
26. Gerrity, T. R., & Henry, C. J. (1990). Principles of Route-to-Route Extrapolation for Risk Assessment. New York: Elsevier.
27. Gentry, P. R., Covington, T. R., Andersen, M. E., & Clewell III, H. J. (2002). Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regulatory Toxicology and Pharmacology, 36, 51-68.
28. Nau, H. (1986). Species differences in pharmacokinetics and drug teratogenesis. Environmental Health Perspectives, 70, 113-129.
29. Clewell III, H. J., Andersen, M. E., Wills, R. J., & Latriano, L. (1997). A physiologically based pharmacokinetic model for retinoic acid and its metabolites. Journal of American Academy of Dermatology, 36, S77-S85.
30. Luecke, R. H., Wosilait, W. D., & Young, J. F. (1997). Mathematical analysis for teratogenic sensitivity. Teratology, 55, 373-380.
31. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., & Andersen, M. E. (1995). Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: Examples with vinyl chloride and trichloroethylene. Chemosphere, 31, 2561-2578.
32. Clewell III, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., & Andersen, M. E. (2001). Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Science of the Total Environment, 274, 37-66.
33. Barton, H. A., & Clewell III, H. J. (2000). Evaluating non-cancer effects of trichloroethylene: Dosimetry, mode of action, and risk assessment. Environmental Health Perspectives, 108(Suppl. 2), 323-334.
34. Clewell III, H. J., Barton, H. A., Maull, E. A., & Andersen, M.E. (2001). Under what conditions is trichloroethylene likely to be a carcinogen in humans? Ecological Risk Assessment, 7, 687-716.
35. Spear, R. (2002). Mathematical modeling in environmental health. Environmental Health Perspectives, 110, A382.
36. Nestorov, I. A., Aarons, L. J., Arundel, P. A., & Rowland, M. (1998). Lumping of whole-body physiologically based pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutics, 26, 21-46.
37. Kohn, M. C. (1997). The importance of anatomical realism for validation of physiological models of disposition of inhaled toxicants. Toxicology and Applied Pharmacology, 147, 448-458.
38. Parham, F. M., Matthews, H. B., & Portier, C. J. (2002). A physiologically based pharmacokinetic model of p,p′- dichlorodiphenylsulfone. Toxicology and Applied Pharmacology, 181, 153-163.
39. Keys, D. A., Wallace, D. G., Kepler, T. B., & Conolly, R. B. (2000). Quantitative evaluation of alternative mechanisms of blood disposition of di(n-butyl) phthalate and mono(n-butyl) phthalate in rats. Toxicological Science, 53, 173-184.
40. Gearhart, J. M., Seckel, C., & Vinegar, A. (1993). In vivo metabolism of chloroform in B6C3F1 mice determined by the method of gas uptake: The effects of body temperature on tissue partition coefficientfs and metabolism. Toxicology and Applied Pharmacology, 119, 258-266.
41. Bogdanffy, M. S., & Sarangapani, R. (2003). Physiologically-based kinetic modeling of vapours toxic to the respiratory tract. Toxicology Letters, 138, 103-117.
42. Andersen, M. E., Eklund, C. R., Mills, J. J., Barton, H. A., & Birnbaum, L. S. (1997). A multi-compartment geometric model of the liver in relation to regional induction of cytochrome P450s. Toxicology and Applied Pharmacology, 144, 135-144.
43. Andersen, M. E., Birnbaum, L. S., Barton, H. A., & Eklund, C. (1997). Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p- dioxin evaluated with a multi-compartment geometric model of hepatic zonation. Toxicology and Applied Pharmacology, 144, 145-155.
44. Pang, K. S. (2003). Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metabolism Disposition, 31, 1507-1519.
45. Beliveau, M., Tardif, R., & Krishnan, K. (2003). Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats. Toxicology and Applied Pharmacology, 189, 221-232.
46. Payne, M. P., & Kenny, L. C. (2002). Comparison of models for the estimation of biological partition coefficients. Journal of Toxicology Environment Health A, 65, 897-931.
47. Poulin, P., & Krishnan, K. (1996). A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicology and Applied Pharmacology, 136, 131-137.
48. Teeguarden, J. G., & Barton, H. A. (2004). Computational modeling of serum binding proteins and clearance in extrapolations across life-stages and species for endocrine active compounds. Risk Analysis, 24, 751-770.
49. Poet, T. S., Weitz, K. K., Gies, R. A., Edwards, J. A., Thrall, K. D., Corley, R. A., Tanojo, H., Hui, X., Maibach, H. I., & Wester, R. C. (2002). PBPK modeling of the percutaneous absorption of perchloroethylene from a soil matrix in rats and humans. Toxicological Science, 67, 17-31.
50. Polak, J., O'Flaherty, E. J., Freeman, G. B., Johnson, J. D., Liao, S. C., & Bergstrom, P. D. (1996). Evaluating lead bioavailability data by means of a physiologically based lead kinetic model. Fundamentals of Applied Toxicology, 29, 63-70.
51. Dankovic, D. A., & Bailer, A. J. (1994). The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. Fundamentals of Applied Toxicology, 22, 20-25.
52. Sweeney, L. M., Gargas, M. L., Strother, D. E., & Kedderis, G. L. (2003). Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicological Science, 71, 27-40.
53. Yuan, J. (1993). Modeling blood/plasma concentrations in dosed feed and dosed drinking water toxicology studies. Toxicology and Applied Pharmacology, 119, 131-141.
54. Barton, H. A., Bull, R., Schultz, I., & Andersen, M. E. (1999). Dichloroacetate (DCA) dosimetry: Interpreting DCA-induced liver cancer dose response and the potential for DCA to contribute to trichloroethylene-induced liver cancer. Toxicology Letters, 106, 9-21.
55. Albanese, R. A., Banks, H. T., Evans, M. V., & Potter, L. K. (2002). Physiologically based pharmacokinetic models for the transport of trichloroethylene in adipose tissue. Bulletin of Mathematical Biology, 64, 97-131.
56. Robinson, P. J. (1992). Physiologically based liver modeling and risk assessment. Risk Analysis, 12, 139-148.
57. Andersen, M. E. (1981). A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state. Toxicology and Applied Pharmacology, 60, 509-526.
58. Medinsky, M. A., Kimbell, J. S., Morris, J. B., Gerde, P., & Overton, J. H. (1993). Advances in biologically based models for respiratory tract uptake of inhaled volatiles. Fundamentals of Applied Toxicology, 20, 265-272.
59. Ramsey, J. C., & Andersen, M. E. (1984). A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicology and Applied Pharmacology, 73, 159-175.
60. Vinegar, A., Jepson, G. W., & Overton, J. H. (1998). PBPK modeling of short-term (0 to 5 min) human inhalation exposures to halogenated hydrocarbons. Inhalation Toxicology, 10, 411-429.
61. Plowchalk, D. R., & Teeguarden, J. (2002). Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicological Science, 69, 60-78.
62. Wang, X., Santostefano, M. J., De Vito, M. J., & Birnbaum, L. S. (2000). Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicological Science, 56, 49-60.
63. Evans, M. V., & Andersen, M. E. (2000). Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): Assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicological Science, 54, 71-80.
64. Mendel, C. M. (1992). The free hormone hypothesis. Distinction from the free hormone transport hypothesis. Journal of Andrology, 13, 107-116.
65. Kohn, M. C., & Melnick, R. L. (2000). The privileged access model of 1,3-butadiene disposition. Environmental Health Perspectives, 108(Suppl. 5), 911-917.
66. Sweeney, L. M., Schlosser, P. M., Medinsky, M. A., & Bond, J. A. (1997). Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats. Carcinogenesis, 18, 611-625.
67. Andersen, M. E., Gargas, M. L., Clewell III, H. J., & Severyn, K. M. (1987). Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicology and Applied Pharmacology, 89, 149-157.
68. Barton, H. A., Creech, J. R., Godin, C. S., Randall, G. M., & Seckel, C. S. (1995). Chloroethylene mixtures: Pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicology and Applied Pharmacology, 130, 237-247.
69. el-Masri, H. A., Constan, A. A., Ramsdell, H. S., & Yang, R. S. (1996). Physiologically based pharmacodynamic modeling of an interaction threshold between trichloroethylene and 1,1-dichloroethylene in Fischer 344 rats. Toxicology and Applied Pharmacology, 141, 124-132.
70. Krishnan, K., Haddad, S., Beliveau, M., & Tardif, R. (2002). Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures. Environmental Health Perspectives, 110(Suppl. 6), 989-994.
71. Lilly, P. D., Thornton-Manning, J. R., Gargas, M. L., Clewell III, H. J., & Andersen, M. E. (1998). Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. Archives of Toxicology, 72, 609-621.
72. Bois, F. Y. (2001). Applications of population approaches in toxicology. Toxicology Letters, 120, 385-394.
73. Allen, B. C., Covington, T. R., & Clewell III, H. J. (1996). Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology, 111, 289-303.
74. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and Industrial Health, 73, 407-484.
75. Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D., Cox, T., & Kedderis, G. L. (2003). The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Analysis, 23, 1221-1238.
76. Keys, D. A., Bruckner, J. V., Muralidhara, S., & Fisher, J. W. (2003). Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene. Toxicological Science, 76, 35-50.
77. Smith, A. E., & Evans, J. S. (1995). Uncertainty in fitted estimates of apparent in vivo metabolic constants for chloroform. Fundamentals of Applied Toxicology, 25, 29-44.
78. Bois, F. Y., Jackson, E. T., Pekari, K., & Smith, M. T. (1996). Population toxicokinetics of benzene. Environmental Health Perspectives, 104(Suppl. 6), 1405-1411.
79. Bois, F. Y., Gelman, A., Jiang, J., Maszle, D. R., Zeise, L., & Alexeef, G. (1996). Population toxicokinetics of tetrachloroethylene. Archives of Toxicology, 70, 347-355.
80. Jonsson, F., Bois, F., & Johanson, G. (2001). Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicological Science, 59, 209-218.
81. Jonsson, F., Bois, F. Y., & Johanson, G. (2001). Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Archives of Toxicology, 75, 189-199.
82. Andersen, M. E., Clewell III, H. J., Gargas, M. L., Smith, F. A., & Reitz, R. H. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicology and Applied Pharmacology, 87, 185-205.
83. Clewell III, H. J., Lee, T., & Carpenter, R.L. (1994). Sensitivity of physiologically-based pharmacokinetic models to variation in model parameters: Methylene chloride. Risk Analysis, 14, 521-531.
84. Clewell III, H. J., Gentry, P. R., Gearhart, J. M., Covington, T. R., Banton, M. I., & Andersen, M. E. (2001). Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicological Science, 63, 160-172.
85. Gentry, P. R., Hack, C. E., Haber, L., Maier, A., & Clewell III, H. J. (2002). An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Toxicological Science, 70, 120-139.
86. Jonsson, F., & Johanson, G. (2001). A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicology and Applied Pharmacology, 174, 99-112.
87. Parker, K. M., & Lera Jr., T. A. (1992). Acute isopropanol ingestion: Pharmacokinetic parameters in the infant. American Journal of Emergency Medicine, 10, 542-544.
88. Burleigh-Flayer, H. D., Gul, M. W., Strother, D. E., Masten, L. W., McKee, R. H., Tyler, T. R., & Gardiner, T. (1994). Isopropanol 13-week vapor inhalation study in rats and mice with neurotoxicity evaluation in rats. Fundamentals of Applied Toxicology, 23, 421-428.
89. Burleigh-Flayer, H., Garman, R., Neptun, D., Sevan, C., Gardiner, T., Kapp, R., Tyler, T., & Wright, G. (1997). Isopropanol vapor inhalation oncogenicity study in Fischer 344 rats and CD-1 mice. Fundamentals of Applied Toxicology, 36, 95-111.
90. Kumagai, S., & Matsunaga, I. (1995). Physiologically based pharmacokinetic model for acetone. Occupational and Environmental Medicine, 52, 344-352.
91. Ward, K. W., & Pollack, G. M. (1996). Comparative toxicokinetics of methanol in pregnant and nonpregnant rodents. Drug Metabolism and Disposition, 24, 1062-1070.
92. Kumagai, S., Oda, H., Matsunaga, I., Kosaka, H., & Akasaka, S. (1999). Uptake of 10 polar organic solvents during short-term respiration. Toxicological Science, 48, 255-263.
93. O'Flaherty, E. J., Scott, W., Schreiner, C., & Bellies, R. P. (1992). A physiologically based kinetic model of rat and mouse gestation: Disposition of a weak acid. Toxicology and Applied Pharmacology, 112, 245-256.
94. Clewell III, H. J., Gearhart, J. M., Gentry, P. R., Covington, T. R., Van Landingham, C. B., Crump, K. S., & Shipp, A. M. (1999). Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Analysis, 19, 547-558.
95. Ward, K. W., Blumenthal, G. M., Welsch, F., & Pollack, G. M. (1997). Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice. Toxicology and Applied Pharmacology, 145, 311-322.
96. Hallier, E., Filser, J. G., & Bolt, H. M. (1981). Inhalation pharmacokinetics based on gas uptake studies. II. Pharmacokinetics of acetone in rats. Archives of Toxicology, 47, 293-304.
97. Andersen, M. E., Gearhart, J. M., & Clewell III, H. J. (1999). Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. Neurotoxicology, 20, 161-171.